Changes for page Neurodiagnoses
Last modified by manuelmenendez on 2025/03/03 22:46
From version 5.1
edited by manuelmenendez
on 2025/01/27 23:04
on 2025/01/27 23:04
Change comment:
There is no comment for this version
To version 34.1
edited by manuelmenendez
on 2025/02/01 13:54
on 2025/02/01 13:54
Change comment:
There is no comment for this version
Summary
-
Page properties (1 modified, 0 added, 0 removed)
-
Attachments (0 modified, 1 added, 0 removed)
-
Objects (1 modified, 2 added, 0 removed)
Details
- Page properties
-
- Content
-
... ... @@ -2,9 +2,10 @@ 2 2 ((( 3 3 (% class="container" %) 4 4 ((( 5 -= Neurodiagnoses =5 += //A new tridimensional diagnostic framework for CNS diseases// = 6 6 7 -This project is focused on developing a novel nosological and diagnostic framework for neurological diseases. Using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies, we aim to create a structured, interpretable, and scalable diagnostic tool. 7 +This project is focused on developing a novel nosological and diagnostic framework for CNS diseases by using advanced AI techniques and integrating data from neuroimaging, biomarkers, and biomedical ontologies. 8 +We aim to create a structured, interpretable, and scalable diagnostic tool. 8 8 ))) 9 9 ))) 10 10 ... ... @@ -12,26 +12,100 @@ 12 12 ((( 13 13 (% class="col-xs-12 col-sm-8" %) 14 14 ((( 15 -= What can I find here? = 16 += What is this about and what can I find here? = 16 16 17 -= =Who has access?==18 += **Overview** = 18 18 19 -We welcome contributions from the global community. Let’s build the future of neurological diagnostics together! 20 20 21 - ==Howto Contribute:==21 +The classification and diagnosis of **central nervous system (CNS) diseases** have long been constrained by **traditional phenotype-based approaches**, which often fail to capture the **complex pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes** that drive disease progression. **Neurodegenerative and psychiatric disorders**, for example, exhibit significant **clinical overlap, co-pathology, and heterogeneity**, making current diagnostic models insufficient. 22 22 23 +This project proposes a **new diagnostic framework**—one that **shifts from symptom-based classifications** to an **etiology-driven, tridimensional system**. By integrating **genetics, proteomics, neuroimaging, computational modeling, and AI-powered annotations**, this approach aims to provide a **more precise, scalable, and biologically grounded method for diagnosing and managing CNS diseases**. 24 + 25 +The **AI-powered annotation system** plays a critical role by **structuring, interpreting, and tracking multi-modal data**, ensuring **real-time disease progression analysis, clinician decision support, and personalized treatment pathways**. 26 + 27 +=== **Project Aim** === 28 + 29 +The project aims to develop a **tridimensional diagnostic framework** with an **AI-powered annotation system**, integrating **etiology, molecular biomarkers, and neuroanatomoclinical correlations** for **precise, standardized, and scalable CNS disease diagnostics**. 30 + 31 +The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on: 32 + 33 +* **Axis 1**: Etiology (genetic or other causes of diseases). 34 +* **Axis 2**: Molecular Markers (biomarkers). 35 +* **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system). 36 + 37 +This methodology enables: 38 + 39 +* Greater precision in diagnosis. 40 +* Integration of incomplete datasets using AI-driven probabilistic modeling. 41 +* Stratification of patients for personalized treatment. 42 + 43 +== **The Role of AI-Powered Annotation** == 44 + 45 +To enhance **standardization, interpretability, and clinical application**, the framework integrates **an AI-powered annotation system**, which: 46 + 47 +* **Assigns structured metadata tags** to diagnostic features. 48 +* **Provides real-time contextual explanations** for AI-based classifications. 49 +* **Tracks longitudinal disease progression** using timestamped AI annotations. 50 +* **Improves AI model transparency** through interpretability tools (e.g., SHAP analysis). 51 +* **Facilitates decision-making for clinicians** by linking annotations to standardized biomedical ontologies (SNOMED, HPO). 52 + 53 +== **The case of neurodegenerative diseases** == 54 + 55 +There have been described these 3 diagnostic axes: 56 + 57 +[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]] 58 + 59 +* ((( 60 +**Axis 1: Etiology** 61 + 62 +* //Description//: Focuses on genetic and sporadic causes, identifying risk factors and potential triggers. 63 +* //Examples//: APOE ε4 as a genetic risk factor, or cardiovascular health affecting NDD progression. 64 +* //Tests//: Genetic testing, lifestyle, and cardiovascular screening. 65 +))) 66 +* ((( 67 +**Axis 2: Molecular Markers** 68 + 69 +* //Description//: Analyzes primary (amyloid-beta, tau) and secondary biomarkers (NFL, GFAP) for tracking disease progression. 70 +* //Examples//: CSF amyloid-beta concentrations to confirm Alzheimer’s pathology. 71 +* //Tests//: Blood/CSF biomarkers, PET imaging (Tau-PET, Amyloid-PET). 72 +))) 73 +* ((( 74 +**Axis 3: Neuroanatomoclinical** 75 + 76 +* //Description//: Links clinical symptoms to neuroanatomical changes, such as atrophy or functional impairments. 77 +* //Examples//: Hippocampal atrophy correlating with memory deficits. 78 +* //Tests//: MRI volumetrics, FDG-PET, neuropsychological evaluations. 79 +))) 80 + 81 +== **Applications** == 82 + 83 +This system enhances: 84 + 85 +* **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials. 86 +* **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking. 87 + 88 +== How to Contribute == 89 + 23 23 * Access the `/docs` folder for guidelines. 24 24 * Use `/code` for the latest AI pipelines. 25 25 * Share feedback and ideas in the wiki discussion pages. 26 26 27 -== Key Objectives :==94 +== Key Objectives == 28 28 29 29 * Develop interpretable AI models for diagnosis and progression tracking. 30 30 * Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources. 31 31 * Foster collaboration among neuroscientists, AI researchers, and clinicians. 99 + 100 +== Who has access? == 101 + 102 +We welcome contributions from the global community. Let’s build the future of neurological diagnostics together! 32 32 ))) 33 33 34 34 106 + 107 + 108 + 109 + 35 35 (% class="col-xs-12 col-sm-4" %) 36 36 ((( 37 37 {{box title="**Contents**"}} ... ... @@ -38,11 +38,14 @@ 38 38 {{toc/}} 39 39 {{/box}} 40 40 41 -== Main contents :==116 +== Main contents == 42 42 43 43 * `/docs`: Documentation and contribution guidelines. 44 44 * `/code`: Machine learning pipelines and scripts. 45 45 * `/data`: Sample datasets for testing. 46 46 * `/outputs`: Generated models, visualizations, and reports. 122 +* [[Methodology>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Methodology/]] 123 +* [[Results>>url:https://wiki.ebrains.eu/bin/view/Collabs/neurodiagnoses/Results/]] 124 +* [[to-do-list>>to-do-list]] 47 47 ))) 48 48 )))
- tridimensional.png
-
- Author
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.manuelmenendez - Size
-
... ... @@ -1,0 +1,1 @@ 1 +149.8 KB - Content
- Collaboratory.Apps.Collab.Code.CollabClass[0]
-
- Public
-
... ... @@ -1,1 +1,1 @@ 1 - No1 +Yes
- XWiki.XWikiRights[3]
-
- Allow/Deny
-
... ... @@ -1,0 +1,1 @@ 1 +Allow - Levels
-
... ... @@ -1,0 +1,1 @@ 1 +view - Users
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.XWikiGuest
- XWiki.XWikiRights[4]
-
- Allow/Deny
-
... ... @@ -1,0 +1,1 @@ 1 +Allow - Groups
-
... ... @@ -1,0 +1,1 @@ 1 +XWiki.XWikiAllGroup - Levels
-
... ... @@ -1,0 +1,1 @@ 1 +view